An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


An efficacy study of itraconazole in the treatment of Penicillium marneffei infection.

J Med Assoc Thai. 1992 Dec;75(12):688-91. Unique Identifier : AIDSLINE MED/93375278
Supparatpinyo K; Chiewchanvit S; Hirunsri P; Baosoung V; Uthammachai C; Chaimongkol B; Sirisanthana T; Department of Medicine, Faculty of Medicine, Chiang Mai; University, Thailand.

Abstract: OBJECTIVES: to evaluate the efficacy and safety of itraconazole in treating P. marneffei infection. METHODS: Ten patients with previously untreated P. marneffei infection were given oral itraconazole at a dose of 200 mg twice a day for 2 months, followed by a dose of 100 mg once a day for 1 month. Efficacy was determined by the clinical and microbiological cure. RESULTS: All but one patient were seropositive for human immunodeficiency virus (HIV). Two patients died during therapy. Clinical improvement was evident in 8 patients. In 7 of these, the mean duration for becoming culture negative was 57 days. Five patients presented with relapse of P. marneffei infection within four months after completion of treatment. CONCLUSIONS: Itraconazole was shown to be effective in the initial treatment of P. marneffei infection. Relapse after treatment is common and long-term suppressive therapy is recommended.
Keywords: Adolescence Adult Antifungal Agents/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Female Human HIV Seropositivity/COMPLICATIONS Ketoconazole/*ANALOGS & DERIVATIVES/ADVERSE EFFECTS/PHARMACOLOGY/ THERAPEUTIC USE Male Middle Age Mycoses/COMPLICATIONS/*DRUG THERAPY Penicillium/*DRUG EFFECTS Support, Non-U.S. Gov't JOURNAL ARTICLEKWDadolescenceadultantifungalagents/adverseeffects/pharmacology/KWDtherapeuticusefemalehumanhivseropositivity/complicationsketoconazole/KWDanalogs&derivatives/adverseeffects/pharmacology/therapeuticusemalemiddleagemycoses/complications/KWDdrugtherapypenicillium/KWDdrugeffectssupport,non-uKWDsKWDgov'tjournalarticle
931230
M93C0768

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .